Scientific Coordination

Coordinator - Inserm

Rodolphe Thiébaut
INSERM,
USMR
146, rue Léo Saignat
33076 Bordeaux
France

Anton Ottavi
INSERM,
USMR
146, rue Léo Saignat
33076 Bordeaux
France
Email : Anton.Ottavi@isped.u-bordeaux2.fr

Project Leader – Janssen

Macaya Douoguih
4-6 Archimedesweg, Leiden,
2333 CN,
Netherlands

Ellen Hubin
Contractor of Janssen Pharmaceutica NV
Beerse 1, Building 103, 1st floor, office 108
Turnhoutseweg 30 | Beerse, Antwerp 2340 (BE)
Email: ehubin1@its.jnj.com

Project Management Team – Inserm Transfert

Patricia Joseph-Mathieu
INSERM TRANSFERT
Paris Biopark
7, rue Watt
75013 Paris
France
Email: patricia.joseph-mathieu@inserm-transfert.fr

Sinéad Quigley
INSERM TRANSFERT
CHU du Vinatier,
Bât 452B, 95, Bd Pinel
69500 Bron
France
Email: sinead.quigley@inserm-transfert.fr

News

  • 27 October 2017

    The 3rd EBOVAC2 Newsletter is now available here. Our October 2017 issue includes an interview with Dr Houreratou Barry, PI of the Centre Muraz site.

  • 12 September 2017

    Clinical Trial Training - Bobo Dioulasso, BURKINA FASO, 23-26 January, 2018 Registration - Enregistrement

  • 12 September 2017

    The 3rd EBOVAC1/2 Annual meeting will be held in Amsteram, the Netherlands 8-10 January 2018. Participants include consortium members and representatives of sites where the project clinical trials are being carried out.

  • 27 June 2017

    The 2nd EBOVAC2 newsletter June 2017 is now available here!

  • 15 May 2017

    Based on final Phase 1 data published in JAMA: The Journal of the American Medical Association, the prime-boost Ebola vaccine regimen induced an antibody response that persisted in 100 percent of healthy volunteers to at least 1 year following vaccination. The results are from the EBOVAC1 study EBL1001 conducted by the Oxford Vaccine Group in the UK.

  • 15 May 2017

    Victoria Derbyshire reporter Catrin Nye went to visit the Oxford Vaccine Group looking for volunteers who participated in the EBL2001 study. Prof. Andrew Pollard (Professor of Paediatric Infection and Immunity and Oxford Vaccine Group PI for EBOVAC1 and EBOVAC2 ) and study volunteers were interviewed.Watch here : http://www.bbc.co.uk/news/uk-39202974

More news
  • Ebola: background

    What is Ebola?

  • Phase 2 trials

    Find out more about EBOVAC2 trials

  • Work programme

    EBOVAC2 is organised into 6 workpackages (WP)

  • Ebola+ programme

    Contributes to efforts to tackle a wide range of challenges in Ebola research